Print

Group Member: Donat Alpar

Contact Details

  • E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Research Interests

  • Cancer evolution
  • liquid biopsy
  • hematopoietic malignancies
  • single-cell genomics
  • NGS technology development

Academic Employment

  • From 06/2015: Next Generation Sequencing Technologist, CeMM, Vienna, Austria
  • 08/2012 - 05/2015: Postdoctoral Fellow, The Institute of Cancer Research - Royal Cancer Hospital, London, UK 
  • 05/2009 - 07/2012: Research Fellow, Department of Pathology, University of Pecs, Hungary (Head of Cancer Cytogenetic Laboratory 01/2008 - 07/2012)
  • 10/2006 - 04/2009: Research Assistant, Department of Pathology, University of Pecs, Hungary

Academic Degrees

  • 03/2009: PhD in Medical Science (summa cum laude), University of Pecs, Hungary
  • 06/2006: MSc in Chemistry, University of Pecs, Hungary
  • 06/2003: MSc in Biology, University of Pecs, Hungary

Scholarships and Awards

  • Selected speaker at the Falling Walls Lab Finale 2014 and A.T. Kearney Scholar at the Falling Walls Conference. Berlin, Germany.
  • Selected participant of the 64th Lindau Nobel Laureate Meeting, Lindau, Germany. 
  • Best Poster Prize at the 44th Congress of the International Society of Paediatric Oncology, London, UK.
  • Marie Curie Intra-European Fellowship (FP7-PEOPLE-2011-IEF) (Best proposal in the category of ‘Life Science’)
  • Fulbright Research Grant (declined in favour of the Marie Curie Fellowship)
  • Scholar of the International Society for Advancement of Cytometry 2011-2015.
  • Travel awards supporting presentations at international conferences (Europe #12, USA #4)  
  • Erasmus Student Study Mobility Scholarship (declined)
  • PhD Full Scholarship by the University of Pecs Medical School.
  • Best oral presentation prize at the Students’ Research Conference 2003, University of Pecs Medical School.

Publications

  • Alpar D*, Barber L*, Gerlinger M. Genetic Intratumor Heterogeneity. In: Gray S (ed). Epigenetic Cancer Therapy. Elsevier (accepted; *equal contribution)
  • Alpar D, Wren D, Ermini L, Mansur MB, van Delft FW, Bateman CM, Titley I, Kearney L, Szczepanski T, Gonzalez de Castro D, Ford AM, Potter NE, Greaves M. Clonal origins of ETV6/RUNX1+ acute lymphoblastic leukemia: studies in monozygotic twins. Leukemia 2015 Apr;29(4):839-846. 
  • Bateman CM*, Alpar D*, Ford AM, Colman SM, Wren D, Morgan M, Kearney L, Greaves MF. Evolutionary trajectories of hyperdiploid ALL in monozygotic twins. Leukemia 2015 Jan;29(1):58-65. (*equal contribution)
  • Alpar D, de Jong D, Holczer-Nagy, Z, Kajtar B, Savola S, Jakso P, David M, Kosztolanyi S, Kereskai L, Pajor L, Szuhai K. Multiplex Ligation-Dependent Probe Amplification and Fluorescence In Situ Hybridization are complementary techniques to Detect Cytogenetic Abnormalities in Multiple Myeloma. Genes Chromosomes and Cancer 2013 Sep;52(9):785-93. 
  • Pajor G, Kajtar B, Pajor L, Alpar D. State-of-the-art FISHing: automated analysis of cytogenetic aberrations in interphase nuclei. Cytometry A 2012 Aug;81(8):649-63. 
  • Nagy Z, Kajtar B, Jakso P, David M, Kosztolanyi S, Hermesz J, Kereskai L, Pajor L, Alpar D. Evolutionary sequence of cytogenetic aberrations during the oncogenesis of plasma cell disorders. Direct evidence at single cell level. Leukemia Research, 2011 Aug;35(8):1114-16.
joomla 1.6 templates free